Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage

NAActive, not recruitingINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Atrial FibrillationStrokeIntracerebral Hemorrhage
Interventions
DEVICE

LAAO

The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.

DRUG

Medical Therapy

Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.

Trial Locations (17)

Unknown

Aarhus University Hospital, Aarhus

Bispebjerg University Hospital, Bispebjerg

Rikshospitalet Glostrup, Glostrup Municipality

Herlev sjukhus, Herlev

Odenses Universitetssjukhus, Odense

Helsinki University Hospital, Helsinki

North Karelia Central Hospital, Joensuu

Kuopio University Hospital, Kuopio

Turku University Hospital, Turku

Vaasa Centralsjukhus, Vaasa

Haukeland Universitetssjukhus, Bergen

Oslo University Hospital, Oslo

Sahlgrenska University Hospital, Gothenburg

Universitetssjukhuset Skåne, Lund

Universitetssjukhuset, Örebro

Danderyd Hospital, Stockholm

Akademiska sjukhuset, Uppsala

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

lead

Karolinska Institutet

OTHER